Deciphering sorafenib resistance in hepatocellular carcinoma via ferroptotic mechanisms - PubMed
3 hours ago
- #Sorafenib Resistance
- #Ferroptosis
- #Hepatocellular Carcinoma
- Sorafenib is a key treatment for advanced hepatocellular carcinoma (HCC), but resistance often limits its effectiveness.
- Ferroptosis, an iron-dependent cell death process, is a promising target to overcome sorafenib resistance.
- The Nrf2/SLC7A11/GPX4 antioxidant axis plays a crucial role in protecting HCC cells from ferroptosis.
- Other pathways like FSP1-CoQ10 and ACSL4/LPCAT3 also regulate ferroptosis in sorafenib-resistant HCC.
- Transcriptional regulators such as P53, ATF4, SAT1, and ABCC5 influence SLC7A11 and ferroptosis pathways.
- Targeting these molecular mechanisms could lead to new therapies to resensitize HCC to sorafenib.